Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

XE, XD & XF: what to know about the Omicron hybrid variants

Greg Basky and Lauren Vogel
CMAJ May 09, 2022 194 (18) E654-E655; DOI: https://doi.org/10.1503/cmaj.1095998
Greg Basky
Saskatoon, Sask.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Vogel
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Canada recently reported its first cases of the Omicron subvariant XE, one of several hybrid variants of SARS-CoV-2 that have emerged since the beginning of this year.

First detected in the United Kingdom in January, XE has genetic material from the Omicron subvariants BA.1 and BA.2, along with three new mutations that are not present in either pre-existing strain.

Hybrid versus mutant

Hybrid or “recombinant” subvariants like XE occur when two different strains of a virus infect the same cell at the same time and blend their genetic material to produce a new variant.

Compared with the slower process of a virus mutating through errors in the replication of its genetic code, recombination can allow for major, rapid changes in transmissibility, severity, and resistance to vaccines and treatments.

According to Susan Hopkins of the UK Health Security Agency, “Recombinant variants are not an unusual occurrence, particularly when there are several variants in circulation, and several have been identified over the course of the pandemic to date.”

Like variants that occur via mutation, most hybrid strains die off relatively quickly, and some may not differ noticeably from their parent variants.

At least two recombinant subvariants in which Delta and Omicron lineages combine — XD and XF — have emerged in Europe in recent months. So far, there is no evidence to suggest that these so-called “Deltacron” strains are more transmissible or cause worse outcomes.

However, the World Health Organization (WHO) has listed XD as a “variant under monitoring” — a label given to SARS-CoV-2 strains with genetic changes that may pose a future risk, but whose epidemiological impact is still unclear.

Community transmission of XE in England has raised concerns that it may have some staying power, too.

Is Omicron XE more transmissible?

XE appears to be roughly 10% more transmissible than its parent variant BA.2, previously the most infectious strain of SARS-CoV-2, according to Maria Van Kerkhove of the WHO.

And in recent weeks, the UK has reported growth rates for XE as much as 20% higher than for BA.2 — albeit with large fluctuations. As of April 5, more than 1000 cases of XE had been reported in England, almost double the number reported on March 25.

Besides the UK and Canada, other countries, including Japan, India, Thailand and Israel, have also identified XE cases, mostly linked with international travel.

The WHO is encouraging public health authorities to monitor Omicron subvariants as distinct lineages. However, the organization will not classify XE as a variant of concern separate from Omicron until it observes major differences in disease transmission or severity.

Canadian officials are actively monitoring Omicron subvariants, including XE, according to Mark Johnson of the Public Health Agency of Canada.

“While preliminary international reports have shown that XE has modestly increased transmissibility compared to BA.2, more data are needed to confirm this finding,” Johnson stated.

Is XE more severe than other strains?

It is too early to know if XE or the other hybrid variants cause more severe disease than other SARS-CoV-2 strains.

According to Grace Roberts, a virologist and research fellow at Queen’s University Belfast, XE likely shares similar characteristics with BA.2 because most of its makeup, including its spike protein, comes from that strain. That means that vaccinations (which target the spike protein) may offer similar levels of protection against XE as for BA.2.

And although both BA.1 and BA.2 appear to be more transmissible than earlier strains of SARS-CoV-2, neither has proven to cause more severe disease.

“It is the devil we know, so to speak,” according to Mark Cameron, an immunologist and associate professor at Case Western Reserve University. “Essentially, a reshuffling of the same deck of cards.”

Tom Peacock, a virologist at Imperial College London, told CNBC that other recombinants that contain spike and structural proteins from different virus families, like XD does, are a “little more concerning.”

How do hybrids complicate pandemic response?

Every time the virus changes there is a risk that current vaccines, which were designed to target the original strain of SARS-CoV-2, will be less effective, according to Horacio Bach, an infectious disease expert at the University of British Columbia.

Lifting public health restrictions also increases the risk of multiple strains of SARS-CoV-2 cocirculating and recombining, Bach told Global News. “As long as you have everything open now — no mask on and nothing — the potential that you generate new mutants, variants or new recombinants is always open.”

Meanwhile, declines in testing for SARS-CoV-2 in many countries have meant that available data on new variants are “progressively less representative, less timely,” wrote Ranjan Mohapatra and colleagues in a letter in the Journal of Medical Virology. “This is hindering realtime tracking of the presence of the virus, [and] how the virus and its variants are spreading and evolving.”

The WHO is urging continued public health precautions, including physical distancing, wearing masks and staying home when sick.

“All of these tools continue to work against reducing the spread,” said Van Kerkhove. Meanwhile, “Vaccinations remain critically important and are incredibly effective at preventing severe disease and death, so get vaccinated when it’s your turn.”

Footnotes

  • Posted on cmajnews.com on April 22, 2022

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 194 (18)
CMAJ
Vol. 194, Issue 18
9 May 2022
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
XE, XD & XF: what to know about the Omicron hybrid variants
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
XE, XD & XF: what to know about the Omicron hybrid variants
Greg Basky, Lauren Vogel
CMAJ May 2022, 194 (18) E654-E655; DOI: 10.1503/cmaj.1095998

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
XE, XD & XF: what to know about the Omicron hybrid variants
Greg Basky, Lauren Vogel
CMAJ May 2022, 194 (18) E654-E655; DOI: 10.1503/cmaj.1095998
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Hybrid versus mutant
    • Is Omicron XE more transmissible?
    • Is XE more severe than other strains?
    • How do hybrids complicate pandemic response?
    • Footnotes
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Saying goodbye to CMAJ News
  • National survey highlights worsening primary care access
  • How Canadian hospitals are decreasing carbon emissions
Show more News

Similar Articles

Collections

  • Topics
    • Infectious diseases: COVID-19
    • Public health

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire